Part I Antimicrobial resistance: Bacterial pathogens of dermatologic significance and implications of rising resistance - 14/05/22

Doi : 10.1016/j.jaad.2021.11.066

Saira George, MD ^a, Fiorinda F. Muhaj, MD ^a,^b, Celine D. Nguyen, BA ^c, Stephen K. Tyring, MD, PhD ^b,^d,^⁎
^a Department of Dermatology, MD Anderson Cancer Center, Houston, Texas
^b Department of Dermatology, University of Texas McGovern Medical School at Houston, Houston, Texas
^c Department of Psychology, Rice University, Houston, Texas
^d Center for Clinical Studies, Houston, Texas

^∗Correspondence to and reprint requests to: Stephen K. Tyring, MD, PhD, Department of Dermatology, University of Texas/Center for Clinical Studies, 1401 Binz Street, Suite 200, Houston TX 77004.Department of DermatologyUniversity of Texas/Center for Clinical Studies1401 Binz StreetSuite 200HoustonTX77004

Abstract

Although the COVID-19 pandemic has been the defining global health crisis of our time, public health officials have been sounding the alarm of another ominous threat for years: an impending antimicrobial resistance crisis.

In dermatology, antibiotics are often used for prolonged courses in the treatment of skin and soft tissue infections and common inflammatory skin conditions, increasing the risk of microbiome alteration and antibiotic-related adverse effects, all while exerting consequential selective pressures on both pathogenic and bystander bacteria. In this review, we hope to raise awareness of the crisis of antimicrobial resistance and review resistance concerns related to dermatology-relevant bacterial pathogens.

Le texte complet de cet article est disponible en PDF.

Key words : antibiotic resistance, antimicrobial resistance, bacteria, clindamycin-resistant Streptococcus pyogenes, dermatology, drug-resistant Mycobacterium tuberculosis, methicillin-resistant Staphylococcus aureus, multidrug-resistant Pseudomonas aeruginosa, resistant Cutibacterium acnes

Abbreviations used : AMR, CA-MRSA, GAS, HA-MRSA, LA-MRSA, MDR, MRSA, SSTI, TB, PBP